Seeking Alpha

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III...

Celgene (CELG) says a Revlimid/ dexamethasone combo met its primary PFS endpoint in a Phase III study of newly diagnosed multiple myeloma patients. Shares +2.5% premarket. (PR)
From other sites
Comments (1)
  • maven pharm
    , contributor
    Comments (178) | Send Message
     
    Celgene will be at $150.00 near term.
    11 Jul 2013, 03:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs